Clinical Trial Update: Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC [Phase 2]

View source ↗

Summary

This Phase 2 neoadjuvant trial evaluates darolutamide alone or with standard therapy in AR-positive stage II-IIIA breast cancer, including triple-negative disea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• NUBEQA (darolutamide) (darolutamide)

Snippet

Sponsor: Vandana Abramson | Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 2 | Status: RECRUITING